Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure

S. S. Gottlieb, M. L. Kukin, M. Yushak, N. Medina, M. Packer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Study Objective: To evaluate the hemodynamic effects of the antiarrhythmic drug, encainide, in the patients with severe chronic heart failure. Design: Unblinded, before-after study. Setting: Referral center for patients with heart failure. Patients: Thirty patients with severe chronic heart failure and a left ventricular ejection less than 40%. Interventions: Invasive hemodynamic measurements were done (using a balloon-tipped thermodilution catheter) before and for 3 hours after a single oral dose of 50 mg of encainide. Measurements and Main Result: Ninety to one hundred and twenty minutes after its administration, encainide produced a significant deterioration in cardiac performance, as reflected by a fall in cardiac index from 2.3 to 1.8 L/min · m2 body surface (mean change 0.5 ± 0.1; P < 0.001), a fall in stroke work index from 26 to 18 g-m/m2 (mean change 8 ± 2; P < 0.001), and an increase in left ventricular filling pressure from 19 to 22 mm Hg (mean change 3 ± 2; P < 0.05). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in 8 of the 30 patients. Serum levels of encainide and its metabolites, O-desmethylencainide and 3-methoxy-O-desmethylencainide, were within the therapeutic range in most patients. Conclusions: Encainide can cause adverse hemodynamic and clinical effects in patients with severe chronic heart failure.

Original languageEnglish (US)
Pages (from-to)505-509
Number of pages5
JournalAnnals of Internal Medicine
Volume110
Issue number7
StatePublished - 1989

Fingerprint

Encainide
Heart Failure
Hemodynamics
Thermodilution
Anti-Arrhythmia Agents
Ventricular Pressure
Referral and Consultation
Catheters
Stroke

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gottlieb, S. S., Kukin, M. L., Yushak, M., Medina, N., & Packer, M. (1989). Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. Annals of Internal Medicine, 110(7), 505-509.

Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. / Gottlieb, S. S.; Kukin, M. L.; Yushak, M.; Medina, N.; Packer, M.

In: Annals of Internal Medicine, Vol. 110, No. 7, 1989, p. 505-509.

Research output: Contribution to journalArticle

Gottlieb, SS, Kukin, ML, Yushak, M, Medina, N & Packer, M 1989, 'Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure', Annals of Internal Medicine, vol. 110, no. 7, pp. 505-509.
Gottlieb SS, Kukin ML, Yushak M, Medina N, Packer M. Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. Annals of Internal Medicine. 1989;110(7):505-509.
Gottlieb, S. S. ; Kukin, M. L. ; Yushak, M. ; Medina, N. ; Packer, M. / Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure. In: Annals of Internal Medicine. 1989 ; Vol. 110, No. 7. pp. 505-509.
@article{2eb69401cd1c411a9ce45388648a42c2,
title = "Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure",
abstract = "Study Objective: To evaluate the hemodynamic effects of the antiarrhythmic drug, encainide, in the patients with severe chronic heart failure. Design: Unblinded, before-after study. Setting: Referral center for patients with heart failure. Patients: Thirty patients with severe chronic heart failure and a left ventricular ejection less than 40{\%}. Interventions: Invasive hemodynamic measurements were done (using a balloon-tipped thermodilution catheter) before and for 3 hours after a single oral dose of 50 mg of encainide. Measurements and Main Result: Ninety to one hundred and twenty minutes after its administration, encainide produced a significant deterioration in cardiac performance, as reflected by a fall in cardiac index from 2.3 to 1.8 L/min · m2 body surface (mean change 0.5 ± 0.1; P < 0.001), a fall in stroke work index from 26 to 18 g-m/m2 (mean change 8 ± 2; P < 0.001), and an increase in left ventricular filling pressure from 19 to 22 mm Hg (mean change 3 ± 2; P < 0.05). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in 8 of the 30 patients. Serum levels of encainide and its metabolites, O-desmethylencainide and 3-methoxy-O-desmethylencainide, were within the therapeutic range in most patients. Conclusions: Encainide can cause adverse hemodynamic and clinical effects in patients with severe chronic heart failure.",
author = "Gottlieb, {S. S.} and Kukin, {M. L.} and M. Yushak and N. Medina and M. Packer",
year = "1989",
language = "English (US)",
volume = "110",
pages = "505--509",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "7",

}

TY - JOUR

T1 - Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure

AU - Gottlieb, S. S.

AU - Kukin, M. L.

AU - Yushak, M.

AU - Medina, N.

AU - Packer, M.

PY - 1989

Y1 - 1989

N2 - Study Objective: To evaluate the hemodynamic effects of the antiarrhythmic drug, encainide, in the patients with severe chronic heart failure. Design: Unblinded, before-after study. Setting: Referral center for patients with heart failure. Patients: Thirty patients with severe chronic heart failure and a left ventricular ejection less than 40%. Interventions: Invasive hemodynamic measurements were done (using a balloon-tipped thermodilution catheter) before and for 3 hours after a single oral dose of 50 mg of encainide. Measurements and Main Result: Ninety to one hundred and twenty minutes after its administration, encainide produced a significant deterioration in cardiac performance, as reflected by a fall in cardiac index from 2.3 to 1.8 L/min · m2 body surface (mean change 0.5 ± 0.1; P < 0.001), a fall in stroke work index from 26 to 18 g-m/m2 (mean change 8 ± 2; P < 0.001), and an increase in left ventricular filling pressure from 19 to 22 mm Hg (mean change 3 ± 2; P < 0.05). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in 8 of the 30 patients. Serum levels of encainide and its metabolites, O-desmethylencainide and 3-methoxy-O-desmethylencainide, were within the therapeutic range in most patients. Conclusions: Encainide can cause adverse hemodynamic and clinical effects in patients with severe chronic heart failure.

AB - Study Objective: To evaluate the hemodynamic effects of the antiarrhythmic drug, encainide, in the patients with severe chronic heart failure. Design: Unblinded, before-after study. Setting: Referral center for patients with heart failure. Patients: Thirty patients with severe chronic heart failure and a left ventricular ejection less than 40%. Interventions: Invasive hemodynamic measurements were done (using a balloon-tipped thermodilution catheter) before and for 3 hours after a single oral dose of 50 mg of encainide. Measurements and Main Result: Ninety to one hundred and twenty minutes after its administration, encainide produced a significant deterioration in cardiac performance, as reflected by a fall in cardiac index from 2.3 to 1.8 L/min · m2 body surface (mean change 0.5 ± 0.1; P < 0.001), a fall in stroke work index from 26 to 18 g-m/m2 (mean change 8 ± 2; P < 0.001), and an increase in left ventricular filling pressure from 19 to 22 mm Hg (mean change 3 ± 2; P < 0.05). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in 8 of the 30 patients. Serum levels of encainide and its metabolites, O-desmethylencainide and 3-methoxy-O-desmethylencainide, were within the therapeutic range in most patients. Conclusions: Encainide can cause adverse hemodynamic and clinical effects in patients with severe chronic heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0024565358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024565358&partnerID=8YFLogxK

M3 - Article

VL - 110

SP - 505

EP - 509

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 7

ER -